These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26695428)

  • 1. The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large 'real world' cohort.
    Wang H; Innes H; Hutchinson SJ; Goldberg DJ; Allen S; Barclay ST; Bramley P; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Dillon JF
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):398-404. PubMed ID: 26695428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of individualized treatment for hepatitis C patients in the real world.
    Chen TM; Huang PT; Lin CH; Tsai MH; Lin LF; Liu CC; Ho KS; Tung JN
    J Gastroenterol Hepatol; 2010 Jan; 25(1):61-9. PubMed ID: 19780879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective chart review to assess the relationship between depression and sustained virological response from interferon treatment for hepatitis C virus.
    Wackernah RC; Lou M; Park SH
    Clin Ther; 2011 Oct; 33(10):1400-5. PubMed ID: 21982383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
    Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
    J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
    Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
    Giusto M; Rodriguez M; Navarro L; Rubin A; Aguilera V; San-Juan F; Ortiz C; López-Andujar R; Prieto M; Berenguer M
    Liver Transpl; 2011 Nov; 17(11):1318-27. PubMed ID: 21761553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Harrison SA; Abdurakhmanov D; Shiffman ML; Bakulin I; Mazur W; Rodriguez-Torres M; Silva GF; Cheinquer H; Messinger D; Connell EV; McKenna M; Tatsch F; Reddy KR;
    J Clin Gastroenterol; 2013 Mar; 47(3):271-9. PubMed ID: 22951527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
    Van Vlerken LG; Van Soest H; Janssen MP; Boland GJ; Drenth JP; Burger DM; Siersema PD; Van Erpecum KJ
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1308-15. PubMed ID: 20729740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
    Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford DH; Cheng W; Weltman M; Rawlinson W; Rizkalla B; Depamphilis JK; Roberts SK;
    Hepatology; 2011 Apr; 53(4):1109-17. PubMed ID: 21480317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
    Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and co-occurrence of hematological complications at the time of diagnosis of chronic hepatitis C in Poland: a cross-sectional study.
    Pierucka M; Stalke P; Zagożdżon P; Smiatacz T; Zaucha JM
    Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):1008-13. PubMed ID: 27271160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.
    Gitto S; Belli LS; Vukotic R; Lorenzini S; Airoldi A; Cicero AF; Vangeli M; Brodosi L; Panno AM; Di Donato R; Cescon M; Grazi GL; De Carlis L; Pinna AD; Bernardi M; Andreone P
    World J Gastroenterol; 2015 Apr; 21(13):3912-20. PubMed ID: 25852276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.